CDH17 CAR t preclinical data featured in Nature Cancer
Filed with ASX · · 3 pages · English
• A CAR T targeting the cell surface marker CDH17 (“CDH17 CAR”), currently under development by Chimeric as CHM 2101, is featured in the prestigious journal Nature Cancer, highlighting its strong scientific merit and innovation • Preclinical data demonstrates strong evidence of efficacy with complete eradication of CDH17-expressing tumours with no toxicity Chimeric Therapeutics (ASX:CHM, “Chimeric
Chimeric Therapeutics Limited on 6ix
Earlier from Chimeric Therapeutics
- Completion of retail component of Entitlement Offer
- Security Class Suspension from Quotation CHMO
- Final Results in Phase 1 Trial of CORE NK Platform
- Chimeric partners with Be the Match BioTherapies
- Successful completion of Institutional Entitlement Offer
Later from Chimeric Therapeutics
- Security Class Reinstatement to Quotation CHMO
- Strategic manufacturing partnership with WuXi ATU
- A$30 million Equity Placement Agreement with L1 Capital
- Licenses viral vector technology from Penn for CDH17
- Patent received in Japan for CLTX CAR technology
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics